explore -WSS

explore

author：fashion 2025-09-28 02:29:00 - browse：93833

Vertex Pharmaceuticals Inc. building — Craig F. Walker/The Boston Globe

Vertex Pharmaceuticals said Friday that, over a year after receiving the company’s stem-cell therapy, two type 1 diabetes patients no longer need to take insulin injections and saw stark reductions in a biological marker of disease.

The results, presented at the American Diabetes Association conference in San Diego, bolstered experts’ hopes that the treatment could provide a functional cure for some patients. In 2021, Vertex announced dramatic results from the first man to receive the treatment, but researchers cautioned it was just one person, who had only been followed for 90 days.

“The data look as good as they could be,” said Jeanne Loring, a stem cell expert and professor emeritus at Scripps Research not involved in the work, in an email.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： As AI regulations shape up, health tech startups beg for clarity

entertainment

WSS

MD Anderson's Padmanee Sharma responds to research credit suit

Videos point to link between seizures and unexplained toddler deaths

As AI regulations shape up, health tech startups beg for clarity

New weight loss drugs work. But how can they best be used?

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Elevance, SCAN deals highlight health insurer acquisition scrutiny

knowledge

explore

entertainment

The high cost of giving birth even with insurance

Flagship Pioneering startup Sonata Therapeutics lays off 21

Guidelines to prevent youth baseball injuries need more muscle

Feng Zhang, Grail founder join forces on new gene editing startup

How one medical school became remarkably diverse

Flagship Pioneering startup Sonata Therapeutics lays off 21

United colonoscopy coverage change 'may cost lives,' doctors say

Medicare Advantage enrollment hits roughly 33.4 million

BioMarin wins approval for gene therapy to treat hemophilia A

Surprise medical billing ban raises prices elsewhere

focus

Medicare Advantage enrollment hits roughly 33.4 million

Morgan Health, with ambitious aims, wants you to know it’s still here

A new drug could help frostbite victims avoid its ravages

As AI regulations shape up, health tech startups beg for clarity

Hospitals are piloting generative AI tools as regulators play catch

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

focus

entertainment

focus

focus